[Federal Register Volume 62, Number 82 (Tuesday, April 29, 1997)]
[Notices]
[Page 23268]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-11036]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.43(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on February 12, 1997, Celgene 
Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059, made 
application to the Drug Enforcement Administration (DEA) for 
registration by letter as a bulk manufacturer of the Schedule II 
controlled substance methylphenidate (1724).
    The firm plans to manufacture methylphenidate for clinical trials, 
formulation studies, and product research and development.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substance may file comments or objections 
to the issuance of the above application.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Acting Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, United States Department of 
Justice, Washington, D.C. 20537, Attention: DEA Federal Register 
Representative (CCR), and must be filed no later than June 30, 1997.

    Dated: March 31, 1997.
Terrance W. Woodworth,
Acting Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration.
[FR Doc. 97-11036 Filed 4-28-97; 8:45 am]
BILLING CODE 4410-09-M